Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-04-23 19:35Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to significant risks of forced delisting, even if the company achieves profitability in 2024 [2][3]. Group 1: Investigation and Delisting Risks - The company has been officially notified of the investigation by the CSRC due to suspected violations of securities laws, and the investigation is ongoing [3]. - If the CSRC's findings result in a determination of major violations as per the Shanghai Stock Exchange listing rules, the company's stock may face forced delisting regardless of its financial performance in 2024 [2][3]. Group 2: Audit Report Concerns - There is a possibility that the annual financial report for 2024 may receive an audit report with a disclaimer of opinion due to several factors, including overdue receivables and ongoing legal issues involving a subsidiary [4]. - The company is actively communicating with its auditing firm to mitigate risks that could affect the audit opinion [4]. Group 3: Legal and Financial Issues - The company's wholly-owned subsidiary is facing criminal charges related to export tax fraud, which could impact the company's operations and financial standing [5]. - Some bank accounts of the company and its subsidiary have been frozen due to overdue loans, which may further affect the company's financing capabilities [5].